Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Final Trade: MSTY, NVO, DKS, HD
06:49pm, Friday, 16'th May 2025
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Novo Nordisk should be thinking about 'what's next,' says Dr. Kavita Patel
06:24pm, Friday, 16'th May 2025
NBC News and MSNBC medical contributor Dr. Kavita Patel joins ‘Fast Money' to discuss Novo Nordisk after the company ousted its CEO on Friday, the competition among obesity drug makers, and more.
Novo Nordisk's CEO Ousted: Deep-Value Opportunity With Sentiment Risks
06:15pm, Friday, 16'th May 2025
Novo Nordisk A/S' CEO exit raises governance questions, but continuity through internal succession likely limits strategic disruption. Valuation reset (~16.5x forward non-GAAP P/E) vs. LLY (~30x) crea
Novo Nordisk should look to the US for its next CEO, analysts say
03:50pm, Friday, 16'th May 2025
As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market
Novo Nordisk Stock: Seems Like A No-Brainer At These Levels
03:26pm, Friday, 16'th May 2025
Novo Nordisk A/S' share price decline is driven by negative sentiment despite strong sales growth, profitability, and efficiency metrics. Competition from Eli Lilly and supply issues have pressured ma
From insulin to Ozempic, history of Novo Nordisk's CEOs
02:18pm, Friday, 16'th May 2025
Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the competitive obesity drug market to American rival Eli
BMO's Evan David Seigerman: Novo Nordisk CEO departure reflects disparity with Eli Lilly
12:29pm, Friday, 16'th May 2025
Evan David Seigerman, BMO Capital Markets head of healthcare research, joins CNBC's 'Money Movers' to discuss reactions to the departure of Novo Nordisk's CEO, what is means for the company's trajecto
Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash
11:50am, Friday, 16'th May 2025
Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments. The stock t
Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share
11:43am, Friday, 16'th May 2025
Novo's shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has failed to
Why Novo Nordisk Stock Just Slipped
11:07am, Friday, 16'th May 2025
Novo Nordisk (NVO -4.34%) stock tumbled 3.9% through 10:45 a.m. ET this morning after the manufacturer of GLP-1 weight loss drugs announced its CEO, Lars Fruergaard Jørgensen, will step down from his
Novo Nordisk CEO to step down, citing market challenges
11:02am, Friday, 16'th May 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss a new leadership shakeup at drug-maker Novo Nordisk.
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price
11:00am, Friday, 16'th May 2025
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.
SPX 6000 Close? Plus, NVO CEO Out, CAVA Dip and Buffett's STZ Position
10:21am, Friday, 16'th May 2025
Kevin Green joins Morning Trade Live as markets open mixed to begin Friday's trading. For the intraday S&P 500 (SPX) ranges KG is watching, he points to 5960-5970 for upward resistance.
Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?
10:11am, Friday, 16'th May 2025
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
Novo Nordisk Stock Suffers After C-Suite Shakeup
09:59am, Friday, 16'th May 2025
Novo Nordisk A/S (NYSE:NVO) is down 3.9% to trade at $63.60 this morning, after a C-suite shakeup.
